The impact of SARS-Cov-2 infection on the periocular injection pain and hypersensitive reaction to botulinum toxin type A: results from clinical questionnaires

ConclusionAdministering botulinum toxin type A three weeks after COVID-19 recovery is a justifiable and comparatively secure approach.
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research